Physician profile
Jonathan Selzer
NPI 1265404271
$5,399.82
in general payments reported to CMS, 2019-2025
28 companies · $841 in 2025
The $841 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $739 · 2020: $467 · 2021: $1,044 · 2022: $787 · 2023: $1,010 · 2024: $513 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,283 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,283.21 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $964.61 | 2023-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Astrazeneca Pharmaceuticals Lp | $675.99 | 2019-2023 | Farxiga |
| Abbvie INC. | $548.86 | 2021-2024 | Vraylar |
| Novo Nordisk INC | $478.80 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $447.52 | 2021-2024 | |
| Astellas Pharma US INC | $425.12 | 2019-2023 | Myrbetriq, Veozah |
| Lilly USA, LLC | $277.42 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.77 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $223.14 | 2020-2023 | Trelegy Ellipta |
| Abbott Laboratories | $123.39 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $119.00 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $108.26 | 2022 | |
| Novartis Pharmaceuticals Corporation | $102.74 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $98.52 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.24 | 2023-2025 | Caplyta |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $59.46 | 2019-2021 | |
| Gilead Sciences, INC. | $58.27 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $54.02 | 2023-2024 | Rexulti |
| Allergan, INC. | $50.94 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $46.63 | 2025 | Uzedy |
| Hikma Pharmaceuticals USA | $45.92 | 2019 | |
| Idorsia Pharmaceuticals US INC | $45.41 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.50 | 2020-2024 | Xifaxan |
| Amarin Pharma, INC. | $30.81 | 2019 | |
| Merck Sharp & Dohme LLC | $19.31 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.46 | 2019 | |
| Pfizer INC. | $15.02 | 2019 | |
| Dexcom, INC. | $14.69 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Selzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.